Skip to content

Study · Observational study · n = 48 · 2025

8 results

Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study.

Oe Y, Nomoto H, Cho KY, Omori T, Nakamura K, Takahashi A, Suzuki Y, Yoshikawa J, Kato-Sato A, Furukawa S, Nishio T, Kitakawa H and 6 more

Show all authors

Miya A, Kameda H, Nakazawa D, Nakamura A, Sakai K, Atsumi T

Therapeutic advances in endocrinology and metabolism17 Sept 2025Cited by 3 (Europe PMC)

PMID40979838 (opens in a new tab)PMCIDPMC12444058 (opens in a new tab)DOI10.1177/20420188251378216 (opens in a new tab)PepBankPUB-40979838
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with diabetes and chronic kidney disease, switching to tirzepatide was linked to lower HbA1c than continued dulaglutide.

    In plain wordsIn patients with diabetes and kidney disease, switching to tirzepatide was linked to lower long-term blood sugar than continued dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c
    Study

    n = 48

    Comparator
    Continued dulaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide significantly reduced HbA1c and body weight compared with the Dula group over 6 months (both p < 0.01).
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  2. 02HumanObservational studyEfficacy outcome

    In patients with diabetes and chronic kidney disease, switching to tirzepatide reduced HbA1c more than continued dulaglutide.

    In plain wordsIn patients with diabetes and chronic kidney disease, switching to tirzepatide reduced HbA1c more than continued dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 48

    Comparator
    Switching to tirzepatide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide significantly reduced HbA1c and body weight compared with the Dula group over 6 months (both p < 0.01).
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  3. 03HumanObservational studyEfficacy outcome

    In patients with diabetes and chronic kidney disease, switching to tirzepatide was linked to lower body weight than continued dulaglutide.

    In plain wordsIn patients with diabetes and kidney disease, switching to tirzepatide was linked to lower weight than continued dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight
    Study

    n = 48

    Comparator
    Continued dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide significantly reduced HbA1c and body weight compared with the Dula group over 6 months (both p < 0.01).
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  4. 04HumanObservational studyEfficacy outcome

    In patients with diabetes and chronic kidney disease, switching to tirzepatide reduced body weight more than continued dulaglutide.

    In plain wordsIn patients with diabetes and chronic kidney disease, switching to tirzepatide reduced body weight more than continued dulaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight reduction
    Study

    n = 48

    Comparator
    Switching to tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide significantly reduced HbA1c and body weight compared with the Dula group over 6 months (both p < 0.01).
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  5. 05HumanObservational studyEfficacy outcome

    In patients with diabetes and chronic kidney disease, continued dulaglutide was linked to increased urine albumin-creatinine ratio.

    In plain wordsIn patients with diabetes and kidney disease, continued dulaglutide was linked to increased urine albumin relative to creatinine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseUrine albumin-creatinine ratio
    Study

    n = 25

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    UACR levels remained stable in the TZP group throughout the study period and increased significantly in the Dula group (p < 0.05).
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  6. 06HumanObservational studyEfficacy outcome

    In patients with diabetes and chronic kidney disease, urine albumin-creatinine ratio remained stable after switching to tirzepatide.

    In plain wordsIn patients with diabetes and kidney disease, urine albumin relative to creatinine remained stable after switching to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeUrine albumin-creatinine ratio
    Study

    n = 23

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    UACR levels remained stable in the TZP group throughout the study period and increased significantly in the Dula group (p < 0.05).
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  7. 07HumanObservational studySafety outcome

    In patients with diabetes and chronic kidney disease, gastrointestinal events occurred after switching to tirzepatide.

    In plain wordsPatients with diabetes and kidney disease reported digestive events after switching to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedGastrointestinal events
    Study

    n = 23

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal events and hypoglycemia were observed in the TZP group, and those subjects who suffered hypoglycemic symptoms were mostly insulin users.
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.
  8. 08HumanObservational studySafety outcome

    In patients with diabetes and chronic kidney disease receiving tirzepatide, hypoglycemic symptoms occurred mostly in insulin users.

    In plain wordsIn patients with diabetes and kidney disease receiving tirzepatide, low blood sugar symptoms occurred mostly in insulin users.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedHypoglycemia
    Study

    n = 23

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal events and hypoglycemia were observed in the TZP group, and those subjects who suffered hypoglycemic symptoms were mostly insulin users.
    2 context sentences
    Summary · context
    This was a prospective, two-arm, observational study performed at a single center.
    Summary · context
    Subjects who switched to tirzepatide (TZP group) and those who continued dulaglutide (Dula group) were observed over 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.